Company Research Report: Peak Bio, Inc.

Company Overview

• Name: Peak Bio, Inc.

• Mission: To find innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer.

• Founded: Founded by Hoyoung Huh, MD, PhD.

• Key People:

• Hoyoung Huh, MD, PhD: Founder, Executive Chairman of the Board

• Satyajit Mitra, PhD: Executive Director, Head of Oncology

• Divya Patel, CPA: Acting CFO

• Danielle Zayat: Human Resources

• Headquarters: San Francisco Bay Area, California.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Development and research in small molecules, antibodies, and antibody-drug conjugates (ADCs) for various significant medical conditions including inflammatory diseases, rare and specialty diseases, and cancer.

Products

PHP-303

• Category: Inflammation

• Description: A novel small molecule inhibitor of Neutrophil Elastase (NE) targeting Alpha-1 Antitrypsin Deficiency (AATD), and potentially applicable to Acute Respiratory Distress Syndrome (ARDS), including COVID-19-related ARDS.

• Key Features:

• Fifth-generation phase II ready NE inhibitor

• Best-in-class NE inhibition at doses of 5mg or higher

• Potential indication for AATD, an unmet need with significant patient populations in the US and Europe

Antibody Drug Conjugates (ADCs)

• Category: Oncology

• Description: Novel anti-cancer agents that combine monoclonal antibodies' selectivity with small-molecule cytotoxic therapeutics' potential.

• Key Features:

• Trop2 ADC targets epithelial-origin solid tumors

• Proprietary PH-1 toxin (spliceosome modulator) enhances tumoricidal activity

• Immune-stimulatory payload approach creating anti-tumor immune memory

• The market opportunity expected to surpass $22B by 2030

Recent Developments

• New Products: No information on new product launches.

• New Features: The incorporation of novel ADC technology utilizing the proprietary PH-1 toxin.

• Partnerships: No information on recent partnerships or collaborations.

• Organizational Developments: Passing of an integral team member, Dr. Patricia Finn, PhD.

• Pipeline Development: Advancements in the adaptability and progress of PHP-303 and the ADC platform, including upcoming milestones for various Phase II initiatives.

Market and Financials

• Market Symbol: OTCQB:PKBO

• Stock Price: $0.07 as of October 17, 2024, with a $0.02 (40%) change.

• Upcoming Milestones:

• Phase II initiation and data collection for PHP-303 in both AATD and ARDS.

• IND submission and Phase II Initiation for novel ADC platforms.

This report reflects the current status of Peak Bio, Inc. based on the latest available data and provides an overview of the company's market activities, product offerings, and organizational structure.